6041 - 6050 of 8620 Results
Title
Year
-
OPENTitle: Decreased Water Mobility Contributes To Increased α‐Synuclein Aggregation**Journal Name: Angewandte Chemie International EditionPublisher: WileyVol: 62Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/anie.202212063Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/anie.202212063Citation Count: 16
- Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice2021OPENTitle: Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in miceJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-021-24567-xBest OA location URL: https://escholarship.org/uc/item/35j6s17tCitation Count: 9
- Induction of the Endoplasmic-Reticulum-Stress Response: MicroRNA-34a Targeting of the IRE1α-Branch2020OPENTitle: Induction of the Endoplasmic-Reticulum-Stress Response: MicroRNA-34a Targeting of the IRE1α-BranchJournal Name: CellsPublisher: MDPI AGVol: 9Issue #: 6Start Page: 1442End Page: 1442Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells9061442Best OA location URL: https://www.mdpi.com/2073-4409/9/6/1442/pdf?version=1592474637Citation Count: 20
- Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson’s Disease at Fall-Risk2023RESTRICTEDTitle: Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson’s Disease at Fall-RiskJournal Name: Neuroscience LettersPublisher: Elsevier BVVol: 817Issue #:Start Page: 137517End Page: 137517Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neulet.2023.137517Citation Count: 2
- The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease2020RESTRICTEDTitle: The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's diseaseJournal Name: European Journal of NeurosciencePublisher: WileyVol: 51Issue #: 12Start Page: 2412End Page: 2422Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/ejn.14679Citation Count: 16
- Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s disease2020RESTRICTEDTitle: Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s diseaseJournal Name: European Journal of NeurologyPublisher: WileyVol: 27Issue #: 5Start Page: 757End Page: 763Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/ene.14177Citation Count: 7
- Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonism2024OPENTitle: Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonismJournal Name: BMC NeurologyPublisher: Springer Science and Business Media LLCVol: 24Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s12883-023-03506-xBest OA location URL: https://bmcneurol.biomedcentral.com/counter/pdf/10.1186/s12883-023-03506-xCitation Count: 1
- NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy2025OPENTitle: NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian EfficacyJournal Name: Movement DisordersPublisher: WileyVol: 40Issue #: 6Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.30175Best OA location URL: https://doi.org/10.1002/mds.30175Citation Count: 1
- Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET2018OPENTitle: Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PETJournal Name: NeuroImage: ClinicalPublisher: Elsevier BVVol: 19Issue #:Start Page: 652End Page: 660Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nicl.2018.05.022Best OA location URL: https://doi.org/10.1016/j.nicl.2018.05.022Citation Count: 27
- Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease2023OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 1End Page: 20Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/10543406.2023.2170400Citation Count: 7